# Diabetes Research Hub — Automated Iteration Report
**Date:** 2026-06-09 (Tuesday)
**Agent:** diabetes-research-iterate (autonomous scheduled run)

## Summary
Made meaningful progress on 3 work-queue priorities: research-path validation, the every-run credibility sweep, and pipeline-integrity verification. No fabrication or overstatement introduced. State and work queue updated.

## 1. Credibility Sweep — CLEAN
- Fabricated PMIDs (>42,000,000): none.
- "zero SAEs" / "zero rejection" / "zero adverse": none.
- "curative" / "achieves a cure": only matches are **detection patterns inside `verify_before_deploy.py`** (the guardrail script itself), not claims.

## 2. Research-Path Validation — 5 paths validated against external evidence
`validated_paths` grew 36 → 41.

| Path | Rating | External evidence |
|------|--------|-------------------|
| empagliflozin → nephropathy | **VALIDATED** | EMPA-KIDNEY, NEJM 2023 (PMID 36331190): ~29% reduction in CKD progression; ~50% slower chronic eGFR decline, diabetic + non-diabetic CKD. |
| semaglutide → retinopathy | **VALIDATED** (safety signal) | SUSTAIN-6 (PMID 27633186) + RCT meta-analysis (PMID 34894326): early-worsening DR signal driven by rapid HbA1c drop in pre-existing retinopathy. Risk, not benefit. FOCUS trial ongoing (~2027). |
| teplizumab → T1D | **VALIDATED** | TN-10, Herold et al., NEJM 2019 (PMID 31180194): single 14-day course delayed clinical onset by a median ~24 months (HR 0.41, 95% CI 0.22–0.78, p=0.006). Basis for FDA Tzield approval. A **delay**, not prevention/cure. |
| empagliflozin → cardiovascular | **VALIDATED** | EMPA-REG OUTCOME, NEJM 2015 (PMID 26378978): 38% lower CV death, 32% lower all-cause mortality, 35% fewer HF hospitalizations in T2D with established ASCVD. |
| metformin → cardiovascular | **PARTIALLY_VALIDATED** | Griffin et al., Diabetologia 2017 (PMID 28776086): 13-RCT meta-analysis; point estimates favored metformin (all-cause mortality RR 0.96, MI 0.89) but **none statistically significant**; UKPDS dominated the pooled weight. Deliberately not rated VALIDATED — genuine uncertainty. |

Caveats were recorded in-state for each (e.g., corpus entries for several paths were preclinical/mouse; the clinical RCT evidence independently confirms the class effect rather than the specific corpus citation).

## 3. Paper Vetting Status
All 285 tracked papers are already adjudicated (272 VETTED, 13 FLAGGED). No new papers entered the system this run (weekly PubMed sweep runs Mondays; today is Tuesday).

## 4. Pipeline Integrity
- `py_compile` across all 60+ scripts in `Analysis/Scripts/`: **ALL OK** (no syntax/import breakage).
- Key state JSON files load cleanly: `agent_state.json`, `research_paths.json`, `combination_validation.json`.
- Master runner healthy: `run_quality_improvements.py --gaps` returns **[OK]**.
- **Full master rebuild not completed this run.** The full pipeline (~30 heavy build scripts + network PMID verification of ~200 PMIDs) runs many minutes and stalled on heavy compute/network steps within the sandbox window. Integrity was verified instead of forcing a multi-minute hang. Queued as a `full_rebuild_verify` item (priority 3) for a longer window.

## 5. Blocked — Requires User
- **git push** of unpushed commits remains blocked: the sandbox HTTPS remote has no GitHub credential helper. This is unchanged and needs a manual push from the user's environment.

## Next-Run Queue Highlights
- `validate_path` (p4): ~20 paths still unvalidated. Next candidates: dapagliflozin→cardiovascular, vitamin_d→autoimmune, rapamycin→islet_transplant, belatacept→islet_transplant, NLRP3→T2D.
- `full_rebuild_verify` (p3): complete full pipeline in a longer window.
- Gap audits cluster late-June/July (Gap #14 due 2026-06-25; Gaps #11/#2/#3/#6 ~early July).

---
*Research synthesis only — not medical advice. All claims trace to a cited source.*
